Asset Value Investors Ltd. has formally requested the resignation of Rohto Pharmaceutical's chairman. The move signals increasing pressure from foreign investors on Japanese corporate governance.
- AVI calls for Chairman Kunio Yamada to step down
- Fund holds approximately 2% stake in the Osaka-based company
- Shareholder proposal submitted for June annual meeting
- AVI cites distortions in corporate governance as primary driver
- Investment in Rohto began in 2024
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.